{"gene":"AP3B2","run_date":"2026-06-09T22:02:43","timeline":{"discoveries":[{"year":2016,"finding":"AP3B2 encodes the neuron-specific beta subunit of the AP-3 adaptor protein complex. Loss-of-function autosomal-recessive mutations in AP3B2 cause early-onset epileptic encephalopathy with optic atrophy, establishing AP3B2 as required for neuronal AP-3 complex function. Unlike AP3B1 (ubiquitous isoform whose loss causes Hermansky-Pudlak syndrome type 2), AP3B2 defects produce a purely neurological phenotype without albinism or hematological symptoms, demonstrating isoform-specific tissue roles.","method":"Whole-exome sequencing of affected individuals, reverse phenotyping of 12 individuals from 8 families, comparison with AP3B1 and AP3D1 phenotypes (genetic epistasis/allelic series)","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — human genetics with allelic series across 8 unrelated families, two orthogonal sequencing methods, but no in vitro biochemical reconstitution of complex assembly","pmids":["27889060"],"is_preprint":false},{"year":2021,"finding":"AP3B2 is a subunit of the vesicle coat protein AP-3 complex and is specifically expressed in central nervous system neurons. Anti-AP3B2 IgG autoantibodies bind to the cytoplasm of Purkinje cells and granular layer synapses, and also to spinal cord gray matter and dorsal root ganglia, consistent with the synaptic vesicle localization of AP3B2 in these neuronal compartments.","method":"Cell-based assay confirming antibody reactivity; immunohistochemical binding pattern analysis in patient serum and CSF","journal":"Journal of neurology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — antibody binding pattern provides indirect localization evidence; single case report, no direct functional assay of AP3B2 protein","pmids":["33988764"],"is_preprint":false},{"year":2026,"finding":"Loss of ap3b2 in a Xenopus laevis CRISPR/Cas9 mosaic F0 tadpole model caused spontaneous seizure-like episodes, increased interhemispheric synchrony detected by GCaMP6s Ca2+ imaging, and downregulation of pathways involving ion transport, GABA neurotransmission, axon guidance, and blood-brain barrier (BBB) transport. BBB integrity was directly compromised (faster sodium fluorescein leakage). Acute losartan (angiotensin receptor blocker) partially rescued locomotor hyperactivity, suggesting a neuroinflammatory component.","method":"CRISPR/Cas9 knockout in Xenopus laevis; genetically encoded Ca2+ sensor (GCaMP6s) imaging; whole-brain transcriptomics; BBB integrity assay (sodium fluorescein leakage); pharmacological rescue with losartan","journal":"Frontiers in neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (imaging, transcriptomics, BBB assay, pharmacological rescue) in a single study using a defined genetic model, but not yet replicated independently","pmids":["41948612"],"is_preprint":false},{"year":2007,"finding":"A novel splice variant of human AP3B2 (AP3B2_v2) was isolated from a fetal brain cDNA library. AP3B2_v2 lacks 22 exons present in AP3B2_v1, producing a 145-amino-acid protein sharing only the C-terminal 145 amino acids with the full-length 1082-amino-acid AP3B2_v1. RT-PCR showed relatively high expression of AP3B2_v2 in brain and testis, with lower levels in other tissues.","method":"Large-scale cDNA library sequencing; RT-PCR expression analysis across adult tissues","journal":"DNA sequence : the journal of DNA sequencing and mapping","confidence":"Low","confidence_rationale":"Tier 3 / Weak — identification of splice variant by cDNA cloning and RT-PCR only; no functional characterization of the variant protein","pmids":["17453999"],"is_preprint":false},{"year":2024,"finding":"In ATM-null mouse cerebellum and ATM-depleted human neuroblastoma cells, AP3B2 was identified as a downstream phosphoproteome target showing confirmed downregulation of ATM/ATR-phosphopeptides, placing AP3B2 as a phosphorylation substrate of ATM kinase in neurons.","method":"Global proteome and phosphoproteome profiling (mass spectrometry) of ATM-null mouse cerebellum and ATM-depleted neuroblastoma cells; ATM/ATR-phosphopeptide identification","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 3 / Weak — mass spectrometry-based phosphoproteomics in a preprint; AP3B2 is one of many listed targets with no dedicated follow-up validation for this specific protein","pmids":["bio_10.1101_2024.06.26.600760"],"is_preprint":true}],"current_model":"AP3B2 encodes the neuron-specific beta subunit of the AP-3 adaptor protein complex, required for synaptic vesicle formation and neurotransmitter release in CNS neurons; loss of function causes developmental and epileptic encephalopathy (DEE48) with disrupted GABA neurotransmission, ion transport, and blood-brain barrier integrity, and the protein may also be a phosphorylation substrate of the ATM kinase."},"narrative":{"mechanistic_narrative":"AP3B2 encodes the neuron-specific beta subunit of the AP-3 adaptor protein complex, a vesicle coat involved in central nervous system neuronal function [PMID:27889060, PMID:33988764]. Autosomal-recessive loss-of-function mutations cause an early-onset epileptic encephalopathy with optic atrophy; in contrast to the ubiquitous AP3B1 isoform, AP3B2 defects produce a purely neurological phenotype, demonstrating isoform-specific tissue roles [PMID:27889060]. The protein localizes to neuronal synaptic compartments, including Purkinje cell cytoplasm, granular-layer synapses, spinal cord gray matter, and dorsal root ganglia [PMID:33988764]. Loss of ap3b2 in a Xenopus model recapitulates spontaneous seizure-like activity with increased interhemispheric synchrony, and is accompanied by downregulation of ion transport, GABA neurotransmission, and axon guidance pathways together with compromised blood-brain barrier integrity, with partial pharmacological rescue by losartan implicating a neuroinflammatory component [PMID:41948612]. Beyond these genetic and model-organism observations, the biochemical mechanism of AP3B2 within neuronal vesicle trafficking has not been directly characterized in the available corpus.","teleology":[{"year":2016,"claim":"Established AP3B2 as a disease gene and defined the AP-3 beta subunit as having a neuron-restricted role distinct from its ubiquitous paralog, answering whether AP-3 isoforms carry tissue-specific functions.","evidence":"Whole-exome sequencing and reverse phenotyping across 8 families, with allelic comparison to AP3B1 and AP3D1","pmids":["27889060"],"confidence":"Medium","gaps":["No in vitro reconstitution of AP-3 complex assembly with AP3B2","Molecular cargo and trafficking step served by AP3B2 not identified","Mechanism linking loss of function to epilepsy and optic atrophy unresolved"]},{"year":2007,"claim":"Identified a brain- and testis-enriched splice variant sharing only the C-terminal region with full-length AP3B2, raising the possibility of isoform diversity in expression.","evidence":"cDNA library sequencing and RT-PCR tissue expression analysis","pmids":["17453999"],"confidence":"Low","gaps":["No functional characterization of the variant protein","Whether the truncated variant assembles into AP-3 or has independent activity unknown"]},{"year":2021,"claim":"Provided indirect localization evidence by mapping where anti-AP3B2 autoantibodies bind, placing the protein in defined neuronal synaptic compartments.","evidence":"Cell-based assay and immunohistochemical binding analysis of patient serum/CSF","pmids":["33988764"],"confidence":"Low","gaps":["Antibody binding is indirect and not a direct functional assay of AP3B2","Single case report, not independently replicated","Does not establish a molecular trafficking function"]},{"year":2024,"claim":"Placed AP3B2 in a signaling context by identifying it as a candidate phosphorylation substrate of ATM kinase in neurons.","evidence":"Global phosphoproteome mass spectrometry of ATM-null mouse cerebellum and ATM-depleted neuroblastoma cells (preprint)","pmids":["bio_10.1101_2024.06.26.600760"],"confidence":"Low","gaps":["Preprint; AP3B2 is one of many listed targets with no dedicated validation","Specific phosphosite and functional consequence unknown","Direct ATM-AP3B2 interaction not demonstrated"]},{"year":2026,"claim":"Provided an in vivo functional model linking AP3B2 loss to seizure phenotypes and downstream disruption of ion transport, GABA neurotransmission, and blood-brain barrier integrity.","evidence":"CRISPR/Cas9 mosaic F0 knockout in Xenopus laevis with GCaMP6s Ca2+ imaging, transcriptomics, BBB leakage assay, and losartan rescue","pmids":["41948612"],"confidence":"Medium","gaps":["Not independently replicated","Mechanistic chain from AP-3 trafficking defect to BBB disruption and neuroinflammation not established","Mosaic F0 model may not capture full loss-of-function phenotype"]},{"year":null,"claim":"The direct molecular function of AP3B2 within neuronal AP-3-mediated vesicle trafficking — its cargo, the trafficking step it serves, and the biochemical basis of its complex assembly — remains uncharacterized.","evidence":"No discovery in the timeline directly assays AP3B2 vesicle trafficking activity or cargo selection","pmids":[],"confidence":"Low","gaps":["No identified cargo molecules","No structural or reconstitution data for AP-3 complex containing AP3B2","Mechanism connecting trafficking role to epilepsy phenotype unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,1]}],"localization":[{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[1]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1]}],"pathway":[{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[0]}],"complexes":["AP-3 adaptor complex"],"partners":[],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q13367","full_name":"AP-3 complex subunit beta-2","aliases":["Adaptor protein complex AP-3 subunit beta-2","Adaptor-related protein complex 3 subunit beta-2","Beta-3B-adaptin","Clathrin assembly protein complex 3 beta-2 large chain","Neuron-specific vesicle coat protein beta-NAP"],"length_aa":1082,"mass_kda":119.1,"function":"Subunit of non-clathrin- and clathrin-associated adaptor protein complex 3 (AP-3) that plays a role in protein sorting in the late-Golgi/trans-Golgi network (TGN) and/or endosomes. The AP complexes mediate both the recruitment of clathrin to membranes and the recognition of sorting signals within the cytosolic tails of transmembrane cargo molecules. AP-3 appears to be involved in the sorting of a subset of transmembrane proteins targeted to lysosomes and lysosome-related organelles. In concert with the BLOC-1 complex, AP-3 is required to target cargos into vesicles assembled at cell bodies for delivery into neurites and nerve terminals","subcellular_location":"Cytoplasmic vesicle, clathrin-coated vesicle membrane; Golgi apparatus","url":"https://www.uniprot.org/uniprotkb/Q13367/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/AP3B2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/AP3B2","total_profiled":1310},"omim":[{"mim_id":"617276","title":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 48; DEE48","url":"https://www.omim.org/entry/617276"},{"mim_id":"607245","title":"ADAPTOR-RELATED PROTEIN COMPLEX 4, BETA-1 SUBUNIT; AP4B1","url":"https://www.omim.org/entry/607245"},{"mim_id":"602166","title":"ADAPTOR-RELATED PROTEIN COMPLEX 3, BETA-2 SUBUNIT; AP3B2","url":"https://www.omim.org/entry/602166"},{"mim_id":"308350","title":"DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 1; DEE1","url":"https://www.omim.org/entry/308350"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":46.0},{"tissue":"parathyroid gland","ntpm":12.0},{"tissue":"pituitary gland","ntpm":29.9},{"tissue":"retina","ntpm":30.5}],"url":"https://www.proteinatlas.org/search/AP3B2"},"hgnc":{"alias_symbol":["NAPTB"],"prev_symbol":[]},"alphafold":{"accession":"Q13367","domains":[{"cath_id":"1.25.10.10","chopping":"40-244","consensus_level":"medium","plddt":93.006,"start":40,"end":244},{"cath_id":"2.60.40.1150","chopping":"861-967","consensus_level":"high","plddt":88.7987,"start":861,"end":967},{"cath_id":"3.30.310.10","chopping":"972-1082","consensus_level":"high","plddt":87.3259,"start":972,"end":1082},{"cath_id":"1.25.40","chopping":"481-610","consensus_level":"medium","plddt":88.5814,"start":481,"end":610}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13367","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q13367-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q13367-F1-predicted_aligned_error_v6.png","plddt_mean":74.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=AP3B2","jax_strain_url":"https://www.jax.org/strain/search?query=AP3B2"},"sequence":{"accession":"Q13367","fasta_url":"https://rest.uniprot.org/uniprotkb/Q13367.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q13367/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q13367"}},"corpus_meta":[{"pmid":"26377319","id":"PMC_26377319","title":"'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook.","date":"2015","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/26377319","citation_count":97,"is_preprint":false},{"pmid":"27889060","id":"PMC_27889060","title":"Autosomal-Recessive Mutations in AP3B2, Adaptor-Related Protein Complex 3 Beta 2 Subunit, Cause an Early-Onset Epileptic Encephalopathy with Optic Atrophy.","date":"2016","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27889060","citation_count":56,"is_preprint":false},{"pmid":"33988764","id":"PMC_33988764","title":"Cerebellar ataxia and myeloradiculopathy associated with AP3B2 antibody: a case report and literature review.","date":"2021","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33988764","citation_count":10,"is_preprint":false},{"pmid":"27440996","id":"PMC_27440996","title":"Variation in PTCHD2, CRISP3, NAP1L4, FSCB, and AP3B2 associated with spherical equivalent.","date":"2016","source":"Molecular vision","url":"https://pubmed.ncbi.nlm.nih.gov/27440996","citation_count":9,"is_preprint":false},{"pmid":"34573230","id":"PMC_34573230","title":"Mild Cognitive Impairment in Chronic Brain Injury Associated with Serum Anti-AP3B2 Autoantibodies: Report and Literature Review.","date":"2021","source":"Brain sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34573230","citation_count":7,"is_preprint":false},{"pmid":"34042275","id":"PMC_34042275","title":"Blended phenotype of combination of HERC2 and AP3B2 deficiency and Angelman syndrome caused by paternal isodisomy of chromosome 15.","date":"2021","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/34042275","citation_count":4,"is_preprint":false},{"pmid":"36356440","id":"PMC_36356440","title":"Novel homozygous AP3B2 mutations in four individuals with developmental and epileptic encephalopathy: A rare clinical entity.","date":"2022","source":"Clinical neurology and neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/36356440","citation_count":3,"is_preprint":false},{"pmid":"17453999","id":"PMC_17453999","title":"Characterization of AP3B2_v2, a novel splice variant of human AP3B2.","date":"2007","source":"DNA sequence : the journal of DNA sequencing and mapping","url":"https://pubmed.ncbi.nlm.nih.gov/17453999","citation_count":1,"is_preprint":false},{"pmid":"41948612","id":"PMC_41948612","title":"Seizures, increased interhemispheric synchrony, altered brain transcriptomics and a leaky blood-brain barrier result from loss of ap3b2 in a CRISPR tadpole model of DEE48.","date":"2026","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/41948612","citation_count":1,"is_preprint":false},{"pmid":"35508598","id":"PMC_35508598","title":"Plasma lncRNA LOC338963 and mRNA AP3B2 are upregulated in paraneoplastic Lambert-Eaton myasthenic syndrome.","date":"2022","source":"Muscle & nerve","url":"https://pubmed.ncbi.nlm.nih.gov/35508598","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.06.26.600760","title":"The ataxia-telangiectasia disease protein ATM controls vesicular protein secretion via CHGA and microtubule dynamics via CRMP5","date":"2024-06-26","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.26.600760","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":8358,"output_tokens":1555,"usd":0.024199,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8325,"output_tokens":2179,"usd":0.04805,"stage2_stop_reason":"end_turn"},"total_usd":0.072249,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2016,\n      \"finding\": \"AP3B2 encodes the neuron-specific beta subunit of the AP-3 adaptor protein complex. Loss-of-function autosomal-recessive mutations in AP3B2 cause early-onset epileptic encephalopathy with optic atrophy, establishing AP3B2 as required for neuronal AP-3 complex function. Unlike AP3B1 (ubiquitous isoform whose loss causes Hermansky-Pudlak syndrome type 2), AP3B2 defects produce a purely neurological phenotype without albinism or hematological symptoms, demonstrating isoform-specific tissue roles.\",\n      \"method\": \"Whole-exome sequencing of affected individuals, reverse phenotyping of 12 individuals from 8 families, comparison with AP3B1 and AP3D1 phenotypes (genetic epistasis/allelic series)\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — human genetics with allelic series across 8 unrelated families, two orthogonal sequencing methods, but no in vitro biochemical reconstitution of complex assembly\",\n      \"pmids\": [\"27889060\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AP3B2 is a subunit of the vesicle coat protein AP-3 complex and is specifically expressed in central nervous system neurons. Anti-AP3B2 IgG autoantibodies bind to the cytoplasm of Purkinje cells and granular layer synapses, and also to spinal cord gray matter and dorsal root ganglia, consistent with the synaptic vesicle localization of AP3B2 in these neuronal compartments.\",\n      \"method\": \"Cell-based assay confirming antibody reactivity; immunohistochemical binding pattern analysis in patient serum and CSF\",\n      \"journal\": \"Journal of neurology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — antibody binding pattern provides indirect localization evidence; single case report, no direct functional assay of AP3B2 protein\",\n      \"pmids\": [\"33988764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Loss of ap3b2 in a Xenopus laevis CRISPR/Cas9 mosaic F0 tadpole model caused spontaneous seizure-like episodes, increased interhemispheric synchrony detected by GCaMP6s Ca2+ imaging, and downregulation of pathways involving ion transport, GABA neurotransmission, axon guidance, and blood-brain barrier (BBB) transport. BBB integrity was directly compromised (faster sodium fluorescein leakage). Acute losartan (angiotensin receptor blocker) partially rescued locomotor hyperactivity, suggesting a neuroinflammatory component.\",\n      \"method\": \"CRISPR/Cas9 knockout in Xenopus laevis; genetically encoded Ca2+ sensor (GCaMP6s) imaging; whole-brain transcriptomics; BBB integrity assay (sodium fluorescein leakage); pharmacological rescue with losartan\",\n      \"journal\": \"Frontiers in neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (imaging, transcriptomics, BBB assay, pharmacological rescue) in a single study using a defined genetic model, but not yet replicated independently\",\n      \"pmids\": [\"41948612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"A novel splice variant of human AP3B2 (AP3B2_v2) was isolated from a fetal brain cDNA library. AP3B2_v2 lacks 22 exons present in AP3B2_v1, producing a 145-amino-acid protein sharing only the C-terminal 145 amino acids with the full-length 1082-amino-acid AP3B2_v1. RT-PCR showed relatively high expression of AP3B2_v2 in brain and testis, with lower levels in other tissues.\",\n      \"method\": \"Large-scale cDNA library sequencing; RT-PCR expression analysis across adult tissues\",\n      \"journal\": \"DNA sequence : the journal of DNA sequencing and mapping\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — identification of splice variant by cDNA cloning and RT-PCR only; no functional characterization of the variant protein\",\n      \"pmids\": [\"17453999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In ATM-null mouse cerebellum and ATM-depleted human neuroblastoma cells, AP3B2 was identified as a downstream phosphoproteome target showing confirmed downregulation of ATM/ATR-phosphopeptides, placing AP3B2 as a phosphorylation substrate of ATM kinase in neurons.\",\n      \"method\": \"Global proteome and phosphoproteome profiling (mass spectrometry) of ATM-null mouse cerebellum and ATM-depleted neuroblastoma cells; ATM/ATR-phosphopeptide identification\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — mass spectrometry-based phosphoproteomics in a preprint; AP3B2 is one of many listed targets with no dedicated follow-up validation for this specific protein\",\n      \"pmids\": [\"bio_10.1101_2024.06.26.600760\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"AP3B2 encodes the neuron-specific beta subunit of the AP-3 adaptor protein complex, required for synaptic vesicle formation and neurotransmitter release in CNS neurons; loss of function causes developmental and epileptic encephalopathy (DEE48) with disrupted GABA neurotransmission, ion transport, and blood-brain barrier integrity, and the protein may also be a phosphorylation substrate of the ATM kinase.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"AP3B2 encodes the neuron-specific beta subunit of the AP-3 adaptor protein complex, a vesicle coat involved in central nervous system neuronal function [#0, #1]. Autosomal-recessive loss-of-function mutations cause an early-onset epileptic encephalopathy with optic atrophy; in contrast to the ubiquitous AP3B1 isoform, AP3B2 defects produce a purely neurological phenotype, demonstrating isoform-specific tissue roles [#0]. The protein localizes to neuronal synaptic compartments, including Purkinje cell cytoplasm, granular-layer synapses, spinal cord gray matter, and dorsal root ganglia [#1]. Loss of ap3b2 in a Xenopus model recapitulates spontaneous seizure-like activity with increased interhemispheric synchrony, and is accompanied by downregulation of ion transport, GABA neurotransmission, and axon guidance pathways together with compromised blood-brain barrier integrity, with partial pharmacological rescue by losartan implicating a neuroinflammatory component [#2]. Beyond these genetic and model-organism observations, the biochemical mechanism of AP3B2 within neuronal vesicle trafficking has not been directly characterized in the available corpus.\",\n  \"teleology\": [\n    {\n      \"year\": 2016,\n      \"claim\": \"Established AP3B2 as a disease gene and defined the AP-3 beta subunit as having a neuron-restricted role distinct from its ubiquitous paralog, answering whether AP-3 isoforms carry tissue-specific functions.\",\n      \"evidence\": \"Whole-exome sequencing and reverse phenotyping across 8 families, with allelic comparison to AP3B1 and AP3D1\",\n      \"pmids\": [\"27889060\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No in vitro reconstitution of AP-3 complex assembly with AP3B2\",\n        \"Molecular cargo and trafficking step served by AP3B2 not identified\",\n        \"Mechanism linking loss of function to epilepsy and optic atrophy unresolved\"\n      ]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified a brain- and testis-enriched splice variant sharing only the C-terminal region with full-length AP3B2, raising the possibility of isoform diversity in expression.\",\n      \"evidence\": \"cDNA library sequencing and RT-PCR tissue expression analysis\",\n      \"pmids\": [\"17453999\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No functional characterization of the variant protein\",\n        \"Whether the truncated variant assembles into AP-3 or has independent activity unknown\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Provided indirect localization evidence by mapping where anti-AP3B2 autoantibodies bind, placing the protein in defined neuronal synaptic compartments.\",\n      \"evidence\": \"Cell-based assay and immunohistochemical binding analysis of patient serum/CSF\",\n      \"pmids\": [\"33988764\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Antibody binding is indirect and not a direct functional assay of AP3B2\",\n        \"Single case report, not independently replicated\",\n        \"Does not establish a molecular trafficking function\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Placed AP3B2 in a signaling context by identifying it as a candidate phosphorylation substrate of ATM kinase in neurons.\",\n      \"evidence\": \"Global phosphoproteome mass spectrometry of ATM-null mouse cerebellum and ATM-depleted neuroblastoma cells (preprint)\",\n      \"pmids\": [\"bio_10.1101_2024.06.26.600760\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Preprint; AP3B2 is one of many listed targets with no dedicated validation\",\n        \"Specific phosphosite and functional consequence unknown\",\n        \"Direct ATM-AP3B2 interaction not demonstrated\"\n      ]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Provided an in vivo functional model linking AP3B2 loss to seizure phenotypes and downstream disruption of ion transport, GABA neurotransmission, and blood-brain barrier integrity.\",\n      \"evidence\": \"CRISPR/Cas9 mosaic F0 knockout in Xenopus laevis with GCaMP6s Ca2+ imaging, transcriptomics, BBB leakage assay, and losartan rescue\",\n      \"pmids\": [\"41948612\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Not independently replicated\",\n        \"Mechanistic chain from AP-3 trafficking defect to BBB disruption and neuroinflammation not established\",\n        \"Mosaic F0 model may not capture full loss-of-function phenotype\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The direct molecular function of AP3B2 within neuronal AP-3-mediated vesicle trafficking — its cargo, the trafficking step it serves, and the biochemical basis of its complex assembly — remains uncharacterized.\",\n      \"evidence\": \"No discovery in the timeline directly assays AP3B2 vesicle trafficking activity or cargo selection\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No identified cargo molecules\",\n        \"No structural or reconstitution data for AP-3 complex containing AP3B2\",\n        \"Mechanism connecting trafficking role to epilepsy phenotype unknown\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"complexes\": [\"AP-3 adaptor complex\"],\n    \"partners\": [],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":4,"faith_total":4,"faith_pct":100.0}}